Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Metropolis Healthcare - Acquires Hitech Diagnostics in South India - ICICI Securities

Posted On: 2021-01-19 05:08:59 (Time Zone: Arizona, USA)


Metropolis Healthcare (Metropolis) has announced its acquisition of 100% stake in Dr. SP Ganesan's Hitech Diagnostic Centre (Hitech) in a cash+stock deal. Hitech is a leading player in South India (primarily Chennai and Bengaluru) with a network of 31 labs and 68 collection centers. This acquisition will help Metropolis in strengthening presence in South India, improving B2C contribution as Hitech has higher B2C proportion in revenue and in driving potential cost synergies in coming years. Metropolis will pay a cash consideration of Rs5.1bn and also issue 4,95,000 equity shares for 100% ownership. The acquisition has been valued at 7.4xSales and ~26.5xEV/EBITDA on FY20 basis (assuming issue of shares at CMP). We estimate these valuations to be ~38% lower than Metropolis' existing valuations. Maintain ADD with a revised target price of Rs2,368/share.

- Hitech acquisition to augment presence in South India with higher B2C focus: Hitech is a well-known diagnostics chain in South India, particularly in Chennai, Bengaluru and other cities of Tamil Nadu. Hitech is the 2nd largest player in Chennai after Metropolis and as per the company, this combined entity will be the leading diagnostic player in Chennai. Hitech's infrastructure network includes 31 laboratories, with 3 NABL & ICMR accredited and 68 collection centers. It caters mainly to mid-segment of the market with higher B2C focus which contributes ~65% to total sales for Hitech. This acquisition will be a strategic fit despite some overlap since Metropolis also has a strong presence in the region. Nevertheless, this transaction will help in driving some cost synergies.

- Financial impact: Hitech had revenue of Rs833mn in FY20 with EBITDA margin similar to Metropolis. 9MFY21 revenue is up ~50% aided by COVID-19 related tests with higher EBITDA margin. We assume 40% revenue growth in FY21E and flat FY22 revenue as COVID-19 contribution will decelerate in our view. Hence, this acquisition will result in ~10% increase in revenue and EBITDA of Metropolis in FY22 and FY23. Management expects this deal to be EPS accretive from day 1. We forecast PAT increase of 1.4% in FY22E and 1.3% in FY23E after assuming gross block addition of Rs700mn, intangibles of Rs1.4bn and goodwill increase of Rs4.1bn. The cash consideration of Rs5.1bn will be funded by internal accruals and debt of up to Rs3bn at an interest cost of less than 6%.

- Outlook: We expect Metropolis to outperform industry growth and register revenue, EBITDA and PAT growth at CAGRs of 18.8%, 22.5% and 21.8%, respectively, over FY20-FY23E. Generation of free cashflow worth ~Rs3bn in FY23E would help in retiring debt. Return ratios will remain strong.

- Valuation: We maintain our ADD rating on the stock with DCF-based revised target price of Rs2,368/share (earlier: Rs2,254/share) implying 45.9xFY23E EPS and 28.2xFY23E EV/EBITDA. Key downside risks: Higher-than-expected competition, pricing pressures and regulatory hurdles.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Warehousing demand expected to grow around 160% to reach 35 million sq. ft in 2021: JLL

Telecom - Spectrum auction: Prudent investment by Bharti Airtel - ICICI Securities

JB Chemicals & Pharmaceuticals - Analyst meet takeaways - ICICI Securities

IPO Review - MTAR Technologies Ltd - ICICI Direct

Auto Sector - Monthly Volume Round-up - Feb 21 - Decent YoY Growth Continues

Aditya Birla Fashion and Retail - Focus on scaling up new businesses - ICICI Securities

Automobiles (wholesale) - Wholesales push continues despite modest retail trends - ICICI Securities

Aditya Birla Capital - Thoughtful (inclusive) conglomerate business evolution commands premium - ICICI Securities

Jubilant Foodworks - Buying in-the-money options - ICICI Securities

Multi Commodity Exchange of India - Play on rising commodity prices? - ICICI Securities

Gladiator Stocks - Sudarshan Chemical - ICICI Direct

Monthly Commodities Outlook - March 2021 - ICICI Direct

ICICI Direct - Monthly Currency Outlook: Rupee to depreciate further towards 75.00 level...

ICICI Direct - Covid Recovery Pulse - E-way bill generation in February 2021 starts on strong note...

Company Update - Virtual JLR Investor Event - Tata Motors - ICICI Direct

Analyst Meet Update - Aditya Birla Fashion and Retail - ICICI Direct

MTAR Technologies Ltd. - IPO - Huge Opportunities from Clean Energy Bodes Well - Reliance Research

ICICI Direct Derivatives Weekly View (February 26): Failure to move above 14700 may extend declines towards 14300...

Bank: Sector Credit Trends - Slows, Yet again - HDFC Securities

Piramal Enterprises - Pharma day highlights - ICICI Securities

Polymer price tracker - PVC prices rise sharply again! - ICICI Securities

Greenply Industries - Growth returns, at an inflection point - ICICI Securities

Tata Motors - JLR future proofing itself with rapid electric transition - ICICI Securities

Dairy - Higher freight cost and increase in Global SMP prices - ICICI Securities

Analyst Meet Update - Nestlé India (Hold): Focus on product innovation, expanding rural reach - ICICI Direct

MTAR Technologies Ltd - A strong player in booming high precision engineering... - Geojit

Rollover Report for February - March 2021 : Angel Broking

Reaction from industry experts on Q3FY21 GDP numbers

M. Govinda Rao, Chief Economic Adviser, Brickwork ratings on Q3FY21 GDP numbers

Mr. Dhiraj Relli, MD & CEO, HDFC securities views on Q3FY21 GDP Growth Number

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research on Q3FY21 GDP

Rollover Analysis - Feb 21, 2021 - YES Securities

Consumer Durables - Demand-driven recovery continues - HDFC Securities

Cement - Demand surprises; earnings upgrade to continue - ICICI Securities

Gladiator Stocks - TeamLease Services - ICICI Direct

Gladiator Stocks - Metals to outshine post multi-year breakout... - ICICI Direct

Company Update - Sundaram Finance - ICICI Direct

Indian pharmaceutical industry to meet an ambition of US$130 billion by 2030 through innovation-led growth: EY-FICCI report

4th Industrial Conclave - Bullish undertone, favourable valuation - HDFC Securities

Sanofi India - Weak quarter; sequential improvement - ICICI Securities

Sunteck Realty - All eyes on upcoming launches - ICICI Securities

Company Update - Tata Motors - ICICI Direct

Q4CY20 Company Update - Mahindra CIE Automotive - ICICI Direct

Event Update - Hindalco - ICICI Direct

EY report launch at BioAsia 2021 - Moving the needle: Healthcare industry in a post-COVID world

Initiating Coverage - Dalmia Bharat Ltd - HDFC Securities Retail Research Desk

Initiating Coverage - Mastek Ltd - HDFC Securities Retail Research Desk

Hindalco Industries - Status quo maintained - ICICI Securities

Tata Motors - India business scaling in the right direction - ICICI Securities

IPO Review - Heranba Industries Ltd



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020